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ABSTRACT
Aging is not a disease. Nevertheless, diseases, including most malignancies, increase in frequency with
advancing age. Although there are many reasons why this might be the case, perhaps most important is that it
takes time to progress through the many steps of carcinogenesis and growth to reach a threshold for diagnosis.
Other factors, including accumulated nonlethal damage to DNA (eg, by free radicals), increased proinflam-
matory factors, and age-associated declines in DNA repair and immune competence, are to some degree
important. The median age for all cancer is approximately 70 years and will become even older over the next
several decades. Myelodysplasia and hematologic malignancies, including lymphoma, myeloma, and leukemia,
can be effectively treated in older age groups, but advanced age presents a number of additional challenges.
With appropriate pretreatment assessment of organ reserve, physical performance, and cognitive function,
individualized (tailored) therapy may ultimately prove to offer the greatest chance for successful outcomes.
Such assessment would also identify those who are likely to benefit frommore aggressive treatments, including
bone marrow or stem cell transplantation.
© 2006 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
Currently, approximately 13% of the population
iving in industrialized countries is older than 65 years,
nd this fraction will rapidly expand over the next
everal decades. This is the result of the aging of the
ost–World War II cohort (baby boomers) and an
ncrease in life span, attributable to public health mea-
ures and improvements in disease management. Like
ost chronic illness, cancer increases in prevalence
ith age [1,2]. Sixty percent of US cancer patients are
lder than 65 years; 31% of cancer patients are older
han 75 years [3]. The burden of deaths from cancer is
lso higher in the elderly: 70% of all cancer deaths
ccur in patients aged 65 years [4]. However, a
etrospective analysis of nearly 29 000 patients in 55
egistration trials found that patients 65 years con-
tituted only 36% of the study population [3]. In the
bsence of evidence derived from well-constructed
rials, physicians must extrapolate from data obtained
rom younger patients and incorporate their own un-
erstanding of the inﬂuence of age and comorbidity e
00n the relevant physiological and pharmacologic pro-
esses. The result is that elderly patients may not
eceive appropriate levels of intervention for their
llness or be fully informed about their treatment
ptions [5,6].
In general, for the treatment of most malignan-
ies, standard treatments result in comparable re-
ponses in older patients. However, for non-Hodgkin
ymphoma and acute leukemias (both of which in-
rease in incidence in late life [4]), experience has
ndicated less successful treatment responses in older
atients [7]. Furthermore, in the treatment of all ma-
ignancies with cytotoxic chemotherapy, certain tox-
cities, including neutropenia and anemia, are more
ommon. As the technologies associated with bone
arrow or stem cell transplantation have improved,
here is an evolving imperative to better understand
he biology of aging and the effect of comorbidities on
reatment response so as to safely adapt this treatment
odality for the large and growing population of
lderly lymphoma patients.
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Aging and Geriatric Medicine
BIn this article, we present an overview of current
opics in biogerontology, including the currently
merging focus on the pathogenesis of frailty. We
hen follow with a more speciﬁc look at the practical
ssues confronting transplantation medicine.
IOLOGY OF AGING
efining Aging
Perhaps the most challenging aspect of the re-
earch on the biology of aging is deﬁning aging. In the
roadest sense, it may be deﬁned as the inability to
aintain homeostasis in the face of challenges as a
esult of time-related changes in physiology. Obser-
ationally, aging can be reﬂected as a passage of time.
e deﬁne this as chronological aging. In other words,
hen an object (living or not) is present at time A and
hen time passes until time B, then the object is chro-
ologically older by the difference in time between
ime B and time A. For inanimate objects, this is a
airly clear concept, although those who like to play
ental games can complicate this. However, when
onsidering the aging of a biological object (ie, an
rganism), we must deﬁne biological aging. In other
ords, all biological objects will pass through chrono-
ogic aging; however, they do not necessarily age at a
onsistent rate biologically. For example, take a new-
orn human and a newborn mouse, both born at the
ame time. Two years later, they are both 2 years old;
hus, they are chronologically identical. However, in
erms of biology, they are at very different places in
heir lives. Speciﬁcally, the human is at a very early
evelopmental stage, is not even able to take care of
imself/herself, and is still growing. In contrast, the
ouse is independent of its parents and is not con-
inuing to develop; in fact, it is nearing the end of its
ife span. Thus, these organisms are of very different
iological ages. In addition to different biological ag-
ng rates due to species differences, the environment
lays a role in the aging process. For example, aged
wins exposed to different environmental conditions
emonstrate different degrees of debilitation and age-
elated biomarkers [8].
ging in Populations
Several concepts that biogerontologists use in-
lude the median life span, maximum life span, and
ectangularization of the survival curve [9,10]. These
oncepts are explained in the context of Figure 1. On
he y-axis is the percentage of the population alive at
he age that is indicated on the x-axis. The dashed line
t 50% represents the median life span for the popu-
ation of interest. Line A represents a population that
as high mortality early in life. Thus, the median life
pan is very low. This curve represents what is be-
ieved to be human survival in primitive/early times. c
B&MThe maximum life span for the population, deﬁned as
he age when the oldest individual in the population
ies, is indicated by the arrowhead on the x-axis.
urve B indicates what occurs as neonatal and child
eath are diminished. The arrow indicates a shift in
he curve (called rectangularization because of the
hange in its shape). The decrease of early mortality is
anifested as an increased median survival. However,
here has been no change in the maximum life span.
o known interventions have been demonstrated to
ncrease the maximum life span in humans. However,
n rodents and many other species, caloric restriction
a decrease in caloric content when all other nutri-
ional components are adequate) has been demon-
trated to increase the maximum life span by upwards
f 40% [9,10]. This would be represented as a change
n line B to line C in Figure 1. As suggested previ-
usly, changes in health care that modulate morbidity
nd mortality can induce rectangularization of the
urvival curve. However, this does not necessarily alter
he maximum life span, which is considered the gold
tandard by which to evaluate antiaging strategies.
echanisms of Aging
No deﬁned mechanism can singly account for the
ging process. However, many theories have been
ostulated (Table 1). These can be broadly divided
nto programmed theories of aging and stochastic the-
ries of aging. Programmed aging implies that an
rganism’s life span is established from the time of
irth (barring unforeseen catastrophic events such as
ar accidents). Programming primarily would occur
hrough genetic mechanisms. In contrast, stochastic
ging implies that an accumulation of random events
ver the life span ultimately dictates the organism’s
ife span. Programmed aging theories as a whole have
ot been well supported by data and essentially have
allen out of favor, although genetics clearly contrib-
tes, at least in the background, to the aging process.
nvironmental factors, including ingestion of foods,
Figure 1. Population survival curve.hemicals, and so on, all contribute to metabolic
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1vents that can induce aging. Several popular theories
f aging are discussed below.
ross-linking Theory of Aging
This theory suggests that as time progresses, bio-
olecules, such as protein and DNA, develop chemical
ross-links [11,12]. The cross-links modify the functions
f these molecules so that they are dysfunctional and
annot continue to support homeostasis. Age-related
ollagen cross-linking provided the initial support for
his theory [13]. Cross-links are composed of intramo-
ecular and intermolecular ester bonds. Collagen cross-
inking is associated with increased cell membrane rigid-
ty, which results in cellular dysfunction [14].
Cross-links are produced by a variety of charged
roups that are produced during metabolism; how-
ver, the most prominent cross-linking molecule is
erived from a nonenzymatic reaction that results in
he chemical bonding of glucose to nucleic acids and
roteins. The reaction between glucose and proteins
s called the Maillard reaction, in which the aldehyde
roup of glucose (–CHO) bonds with the amino group
–NH2) of a Schiff base, producing what are termed
madori products [15]. The Amadori products on the
roteins change their molecular structure over time to
orm advanced glycosylation end products. The ad-
anced glycosylation end products can cross-link with
ther proteins, thus resulting in a major inhibition of
rotein function [16] that can ultimately result in
ging of the organism.
ree Radical Theory of Aging
The free radical theory of aging promotes the idea
hat lifelong accumulation of radical-mediated dam-
ge to biologically important macromolecules is the
asis for aging [17]. Although cause and effect have
able 1. Theories of Aging
Theory
enetic based
Mutation accumulation An evolutionary-based theo
not selected against
Antagonistic pleiotropy Genes that provide a benefi
Gene expression Changes in gene expression
Error catastrophe Decreased accuracy of gene
Disposable soma Somatic tissue is programm
becomes disposable
tochastic based
Wear and tear Injuries to tissues accumula
Free radical Oxidative stress induces da
over time
Cellular senescence Senescence of cells results
Telomere theory Loss of telomere length ove
Cross-linking Molecules cross-link with ti
mmunologic Immunologic function decli
euroendocrine The hypothalamus become
dysfunctionot been proven, several lines of experimental evi- t
02ence support this theory. For example, (1) reactive
xygen species production from cells increases with
ge in a divergent variety of species, from ﬂies [18] and
ats [19] to humans [20], and (2) reactive oxygen spe-
ies–induced damage to biomolecules [21] increases
ith age. It has been suggested that an age-associated
ecrease of antioxidant enzyme levels may lead to the
ncreased reactive oxygen species–mediated damage in
variety of tissues [22,23], although some may refute
his hypothesis [24]. Differences in sex, site, and sam-
ling time in relation to feeding may account for these
iscrepancies. Regardless of the inciting cause, the
ge-related damage that oxidative stress induces has
ound general acceptance as contributing to the aging
rocess.
IOLOGICAL EXPLANATIONS FOR FRAILTY
Among gerontologists and geriatricians, there has
een an increased appreciation of a syndrome that
ccurs in some, but not all, older people and occurs
ven in the absence of underlying disease. Thus, the
frailty phenotype” and its physiologic antecedents
ave become a major focus of research in geriatric
edicine. The National Institute on Aging and the
merican Geriatrics Society recently conducted a
-day workshop on the pathophysiology of frailty [25].
Findings to date suggest that the properties of
ystems, such as robustness, need to be viewed at
ultiple levels from cellular to organismal function
nd that the interaction of the varied systems affects
he communication network that is essential for opti-
al overall function. Components of both the clinical
resentation and the physiologic phenotype may af-
ect both cellular and organismal function and molec-
lar characteristics. The concept is consistent with the
Description
suggests that mutations that promote age-related declines are
g youth are harmful during aging
ime promote aging
cription/translation with aging produces dysfunctional proteins
stay alive only through successful reproduction and then
r time
o biomolecules (lipid, protein, and DNA) that accumulates
n failure
results in replicative senescence of cells
ulting in dysfunction
h aging, resulting in either infection or autoimmune disease
esponsive to hormone signals over time, resulting in endocrinery that
t durin
over t
trans
ed to
te ove
mage t
in orga
r time
me, res
nes wit
s less rheory of Csete and Doyle [26] regarding the layers of
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Beedback regulation that underlie the complexity and
obustness of organisms. Thus, emerging research
imed at understanding the pathophysiology of frailty
eans heavily on the implementation of techniques in
ystems biology.
SSESSING THE OLDER PATIENT
OR TRANSPLANTATION
ransplantation for Older Patients
Rapid advances in the ﬁeld of allogeneic hematopoi-
tic cell transplantation (HCT) have contributed to im-
roved transplantation tolerability and reductions in
cute nonrelapse mortality. Although reduced-intensity
onditioning regimens have been credited, more tolera-
le immune suppression, molecular HLA matching, pe-
ipheral blood progenitor cells (to hasten hematologic
ecovery), and better supportive care have also been
nstrumental. For example, the past 5 years have wit-
essed enhanced detection and treatment of the most
roblematic infections in the post-HCT setting, such
s cytomegalovirus and aspergillosis [27-29].
With increasing recipient age, transplant-related
ortality (TRM) rises both from regimen-related tox-
cities and graft-versus-host disease [30,31]. HCT
uitability in older adults is an emerging clinical di-
emma because disease incidence and more aggressive
ehavior characterize many hematologic malignancies
ith advancing age, in addition to the changing com-
osition of industrialized societies to an older popu-
ation (Artz, Bone Marrow Transplant, 2005, in press).
Improved tolerability has led to reexamination of
tandard age limits and acceptable comorbid condi-
ions, and this has opened the possibility of HCT to a
arger pool of patients {van Besien, 2005 #249}. Nu-
erous series demonstrate HCT feasibility for pa-
ients who are 50 years, have comorbid conditions,
r both, with varying TRM [32-34].
valuation of Older Patients: Age
Chronologic age represents a surrogate of health
tatus. Clearly, comorbidity and functional limitations
isproportionately affect older adults [35], and older
ancer patients may have more comorbid conditions
han those without cancer. However, the heterogene-
ty of older adults limits inferences regarding health
tatus that rely only on age [36]. Age is better estab-
ished as a marker for survival in longer-term
ollow-up [37]. The published literature on older pa-
ients receiving HCT offers limited guidance on esti-
ating transplantation tolerability because of a lack of
nformation on enrolled patients. The underrepresen-
ation and patient selection of the elderly in cancer
rials are established [3,38]. One can expect even more
igniﬁcant patient selection for HCT, thus the sug-
estion not to use chronologic age for eligibility [39]. p
B&MTCharacterizing the heterogeneous older popula-
ion requires additional clinical information on health
tatus. Comorbidity and functional status represent
he primary areas of interest, although other domains,
uch as emotional support, caregivers, and social sit-
ation, play a role. Routine pre-HCT comorbidity
valuation entails objective measures of single-organ
unction, such as pulmonary, hepatic, kidney, and he-
atic testing, and may allow predicting organ-speciﬁc
oxicity [40]. Although these measures are highly re-
roducible, they have limited utility in determining
ransplantation suitability.
omorbidity
More comprehensive comorbidity scores gener-
ted from the known medical conditions, aside from
he disease itself, have considerable predictive power
or cancer-related toxicity and survival [41-47]. Mul-
iple validated tools exist. Most instruments have in-
eger scores starting at 0 for no conditions, with points
iven for every additional condition and more than 1
oint given for severe comorbid illnesses. The Charl-
on Comorbidity Index (CCI) is one of the simplest
nd most widely used instruments [37,48].
Recent data from multiple groups have con-
rmed that the CCI predicts transplantation toler-
nce [33,34,49-51]. For example, the Seattle group
eported increased grade IV toxicity and nonrelapse
ortality [49,51]. The CCI affords limited discrimi-
ative capacity for HCT tolerability, because most
atient score from 0 to 1. In addition, no index exists
hat captures conditions necessarily speciﬁc to HCT,
ecause most instruments were developed to estimate
he overall survival of elderly persons, rather than
urvival in the context of HCT. For example, infec-
ions are typically not accounted for. Sorror et al. [50]
ecently developed a revised index for HCT that is
ased on the CCI. Incorporation of additional condi-
ions allowed greatly enhanced sensitivity, with abnor-
al scores by the revised index in 62% of patients,
ompared with only 12% on the CCI. The predictive
alidity for 2-year TRM for low-, intermediate-, and
igh-risk groups was 59%, 49%, and 17%, respec-
ively, by the CCI, compared with 71%, 60%, and
4% for the new index. Although these differences are
tatistically signiﬁcant, the beneﬁt to clinical decision
aking is less clear.
unctional Status
Functional status reproducibly serves as an invalu-
ble tool for critical health status assessment among
he elderly. Basic measures of functional status, such
s impairment in activities of daily living, predict mor-
ality better than do standard measures of illness [52].
n addition, functional status and comorbidity inde-
endently predict toxicity and survival in cancer pa-
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1ients [42-45,53]. Oncologists commonly use simple
ubjective measures of performance status (PS), such as
arnofsky or Eastern Cooperative Oncology Group PS.
lthough not frequently reported in HCT studies, PS
emains a powerful, and probably underappreciated,
redictor of survival [33,54,55]. Limited data suggest
hat PS has independent, if not superior, prognostic
apacity in the HCT setting [56,57].
Standard functional measures with objective and
ubjective components used in health status assess-
ent by geriatricians enable better delineation of che-
otherapy toxicity. In one study by Repetto and Bal-
ucci [45], 37% of subjects with a PS of 2 had
imitations in normal daily activities (ie, abnormal
nstrumental activities of daily living), thus afﬁrming
he importance of functional evaluation.
ther Domains
Additional considerations in the health status de-
ermination of older individuals include mental status,
motional status, social support, geriatric syndromes,
nd nutrition. Although the effects of these domains
n HCT outcome remain unknown, identifying lim-
tations is central to geriatric assessment. The consid-
rable acute and chronic toxicities from HCT place a
remendous physiologic stress on patients. Subtle ab-
ormalities may lead to potentially devastating com-
lications. Data outside of the HCT setting indicate
hat comprehensive geriatric assessment detects addi-
ional geriatric-speciﬁc problems and may improve
utcome [58,59]. Inferences can easily be made to the
CT population. For example, delirium occurs in up
o 50% of HCT recipients [60]. Because dementia
redisposes to delirium in hospitalized patients and
ecause delirium leads to prolonged hospitalizations
nd complications [61], identifying occult baseline
ognitive impairment may allow strategies for early
dentiﬁcation and treatment. Similar approaches could
e used for problems documented in other geriatric
omains, such as nutrition.
uture Directions
Studies using more comprehensive evaluation
hould enhance the characterization of older patients
hrough systematic determination of comorbidity,
unctional status, and other geriatric domains. Al-
hough the ﬁeld can build on the foundations of ge-
iatrics and geriatric oncology, assessment will require
ailoring to the expected complications of HCT. On-
oing prospective studies hold promise to identify
easures that accurately predict HCT tolerance.
Even with better instruments to estimate HCT
olerability, several questions need to be addressed.
an monitoring or treatment of pretransplantation
imitations improve outcome? Will alternations in the
reatment regimen (reduced-intensity conditioning,
04-cell depletion, or both) mitigate complications in
igh-risk patients? Most importantly, will the decision
o pursue HCT be inﬂuenced by the additional infor-
ation afforded by such an assessment?
ONCLUSION
In summary, age alone should not exclude patients
rom HCT. Patients, especially those 50 years of
ge, should have comorbid conditions and PS pro-
pectively assessed and tabulated. Each institution
hould consider analyzing the data to estimate HCT
olerance, because the effects of patient selection, sup-
ortive care, and preparative regimens may vary.
hen clinical trials of older patients undergoing
CT are reported, comorbidity scores that use a
alidated index, such as the CCI, as well as PS, should
e reported to fully characterize the patient popula-
ion. Developing more reﬁned instruments speciﬁc for
CT to better assess older patients is a priority.
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